This morning, (28.10.15), MannKind Corporation celebrated its Dual Listing at the Tel Aviv Stock Exchange by taking part in the "Opening Bell Ceremony".
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases such as diabetes. Our only approved product, AFREZZA, (insulin human [rDNA origin]) inhalation powder, is a rapid-acting inhaled insulin that was approved by the U.S. Food and Drug Administration on June 27, 2014 to improve glycemic control in adult patients with diabetes.
Yossi Beinart, TASE CEO said: "Israel as a Start Up Nation, is the home of Technology and Biomed Industries and The Tel Aviv Stock Exchange make various steps to encourage public companies in this sector. MannKind Corporation has a long lasting Israeli relationship along with Mr. Alfred Mann, ( Founder and Chief Executive of MannKind), who stands behind some of the Israeli breakthrough's in the medical device developements. I hope and believe that Mannkind Corporation's dual listing is another step in its relations with Israel and the Israeli Biomed community, which will broaden their presence here".
Matthew Pepper, Vice president and CFO of MannKind, who took the stage and rang the TASE opening bell added, "I am proud and excited to be in Israel to list Mannkind for trade on the TASE. This is the first step of the company in Israel which reflects our intention to maintain a long term relationship with the Israeli capital market and the local biomedical industry. MannKind managed to promote a product throughout all stages of development to marketing approval and to market. Our ability to deliver insulin through an inhaler involves a revolutionary technology and I hope that our collaboration with Sanofi will help the inhaler also enter the Israeli hospitals soon. We are going to continue to develop the unique technology also for additional medical indications. "
From right to left:
Drorit Vilnai, Head of Listing Unit; Amnon Mandelbaum, Senior Managing Director at Sunrise Securities; Avigail Shenhav-Tal, Senior Manager in the Listing Unit; Yossi Beinart, CEO of the TASE; Matthew J. Pfeffer, Vice President and Chief Financial Officer of MannKind ; Amnon Neubach, Chairman of the Board of TASE.
Photo: Kobi Kantor
